van Elmpt, W., De Ruysscher, D., van der Salm, A., Lakeman, A., van der Stoep, J., Emans, D., et al. (2012) The PET-Boost Randomised Phase II Dose-Escalation Trial in Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 104, 67-71.
http://dx.doi.org/10.1016/j.radonc.2012.03.005

has been cited by the following article:

• TITLE: Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose

  AUTHORS: James K. Russo, Daniel Grass, Kent E. Armeson, John Stahl, Tarek Dufan, John Reynolds, Aaron Luebke, Anand K. Sharma

  KEYWORDS: IMRT, NSCLC, Toxicity, Survival, Patterns of Failure, Chemotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.11, October 7, 2015

  ABSTRACT: Purpose: To investigate the toxicity, survival and patterns of failure in patients with advanced lung cancer treated with intensity modulated radiation therapy (IMRT) and chemotherapy. Methods and Materials: Retrospective chart review of 68 total patients: 46 academic and 22 community center. Endpoints: Grade ≥ 3 pneumonitis, Grade ≥ 2 esophagitis, local, regional and distant failure, progression-free survival (PFS) and overall survival (OS). Results: For the academic center patients, median follow-up was 19.2 months. Esophagitis: 0% Grade 3, 35% Grade 2, no significant difference between dose bins: